

**GATA 3 EXPRESSION IN BREAST CARCINOMA, AND ITS ASSOCIATION WITH ER, PR, HER 2 NEU STATUS, A 3 YEARS STUDY IN A TERTIARY CARE CARE CENTRE”**

**Dr Ritu Porna Botuah ,PG Dr. Vijaya Baskar, MD, Assistant professor Prof.**

**Dr. Rajavelu Indira, Professor of Pathology, Madras Medical College, Chennai.**

**Introduction:** Some recent studies has shown that expression of GATA-3 is limited to carcinoma of breast and carcinoma of urinary bladder and therefore this IHC marker may be a sensitive and specific marker for metastatic breast carcinomas.

**Methods:** In this study, to evaluate the expression of GATA-3 in breast carcinoma and to compare the GATA-3 expression with already known ER, PR and HER 2 neu status of breast carcinoma cases.

**Materials and methods:** This is a study of both prospective and retrospective type for a period of 3 years. For our study we did IHC test for 50 cases of invasive breast carcinoma with already known ER , PR and HER 2 NEU status .

**Observation and results:** In our study out of 50 cases 36 (72%) showed GATA 3 reactive and 14 cases (28%) cases were negative and 36 (72%) case showed positive result.

Among the luminal subtype 91% showed GATA3 positivity and 2 cases (9%) showed negative reaction to .

**Conclusion:** From the study it is found that GATA3 may not be shown to be a prognostic factor. GATA 3 expression in triple negative tumors may be an important clue to establish this marker for metastatic breast carcinoma (MBC).

#### **ABBREVIATIONS**

IHC	-	Immunohistochemistry
ER	-	Estrogen Receptor
PR	-	Progesterone Receptor
HER 2	-	Human Epidermal Growth Factor Receptor- 2
GATA	-	Family of transcription factor characterized by ability to bind with the “ GATA” sequence of DNA.